Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 104


Equilibrium between host and cancer caused by effector T cells killing tumor stroma.

Zhang B, Zhang Y, Bowerman NA, Schietinger A, Fu YX, Kranz DM, Rowley DA, Schreiber H.

Cancer Res. 2008 Mar 1;68(5):1563-71. doi: 10.1158/0008-5472.CAN-07-5324.


Targeting the stroma by T cells to limit tumor growth.

Zhang B.

Cancer Res. 2008 Dec 1;68(23):9570-3. doi: 10.1158/0008-5472.CAN-08-2414. Review.


Recurrence of intracranial tumors following adoptive T cell therapy can be prevented by direct and indirect killing aided by high levels of tumor antigen cross-presented on stromal cells.

Thomas DL, Kim M, Bowerman NA, Narayanan S, Kranz DM, Schreiber H, Roy EJ.

J Immunol. 2009 Aug 1;183(3):1828-37. doi: 10.4049/jimmunol.0802322. Epub 2009 Jul 10.


Two-photon imaging of intratumoral CD8+ T cell cytotoxic activity during adoptive T cell therapy in mice.

Breart B, Lemaître F, Celli S, Bousso P.

J Clin Invest. 2008 Apr;118(4):1390-7. doi: 10.1172/JCI34388.


The duration of TCR/pMHC interactions regulates CTL effector function and tumor-killing capacity.

Riquelme E, Carreño LJ, González PA, Kalergis AM.

Eur J Immunol. 2009 Aug;39(8):2259-69. doi: 10.1002/eji.200939341.


Loss of CTL function among high-avidity tumor-specific CD8+ T cells following tumor infiltration.

Janicki CN, Jenkinson SR, Williams NA, Morgan DJ.

Cancer Res. 2008 Apr 15;68(8):2993-3000. doi: 10.1158/0008-5472.CAN-07-5008.


Efficacy of IL-2- versus IL-15-stimulated CD8 T cells in adoptive immunotherapy.

Mueller K, Schweier O, Pircher H.

Eur J Immunol. 2008 Oct;38(10):2874-85. doi: 10.1002/eji.200838426.


Transforming growth factor-beta-mediated signaling in T lymphocytes impacts on prostate-specific immunity and early prostate tumor progression.

Diener KR, Woods AE, Manavis J, Brown MP, Hayball JD.

Lab Invest. 2009 Feb;89(2):142-51. doi: 10.1038/labinvest.2008.123. Epub 2008 Dec 15.


Modeling the CD8+ T effector to memory transition in adoptive T-cell antitumor immunotherapy.

Rolle CE, Carrio R, Malek TR.

Cancer Res. 2008 Apr 15;68(8):2984-92. doi: 10.1158/0008-5472.CAN-07-3040.


The role of tumor stroma in the interaction between tumor and immune system.

Blankenstein T.

Curr Opin Immunol. 2005 Apr;17(2):180-6. Review.


Secretion of tumor-specific antigen by myeloma cells is required for cancer immunosurveillance by CD4+ T cells.

Corthay A, Lundin KU, Lorvik KB, Hofgaard PO, Bogen B.

Cancer Res. 2009 Jul 15;69(14):5901-7. doi: 10.1158/0008-5472.CAN-08-4816. Epub 2009 Jun 30.


Myeloid-derived suppressor cells in inflammatory bowel disease: a new immunoregulatory pathway.

Haile LA, von Wasielewski R, Gamrekelashvili J, Krüger C, Bachmann O, Westendorf AM, Buer J, Liblau R, Manns MP, Korangy F, Greten TF.

Gastroenterology. 2008 Sep;135(3):871-81, 881.e1-5. doi: 10.1053/j.gastro.2008.06.032. Epub 2008 Jun 12.


Modified tumour antigen-encoding mRNA facilitates the analysis of naturally occurring and vaccine-induced CD4 and CD8 T cells in cancer patients.

Knights AJ, Nuber N, Thomson CW, de la Rosa O, Jäger E, Tiercy JM, van den Broek M, Pascolo S, Knuth A, Zippelius A.

Cancer Immunol Immunother. 2009 Mar;58(3):325-38. doi: 10.1007/s00262-008-0556-8. Epub 2008 Jul 29.


Combinations of tumor-specific CD8+ CTLs and anti-CD25 mAb provide improved immunotherapy.

Ohmura Y, Yoshikawa K, Saga S, Ueda R, Kazaoka Y, Yamada S.

Oncol Rep. 2008 May;19(5):1265-70.


Induction of both CD8+ and CD4+ T-cell-mediated responses in colorectal cancer patients by colon antigen-1.

Maccalli C, Di Cristanziano V, Fodale V, Corsi D, D'Agostino G, Petrangeli V, Laurenti L, Guida S, Mazzocchi A, Arienti F, Perrone MP, Castelli C, Rivoltini L, Zagonel V, Tartaglia M, Parmiani G, Belardelli F.

Clin Cancer Res. 2008 Nov 15;14(22):7292-303. doi: 10.1158/1078-0432.CCR-08-0832. Epub 2008 Oct 30.


Immunotherapy: target the stroma to hit the tumor.

Kammertoens T, Schüler T, Blankenstein T.

Trends Mol Med. 2005 May;11(5):225-31. Review.


Anti-tumoral effect of active immunotherapy in C57BL/6 mice using a recombinant human VEGF protein as antigen and three chemically unrelated adjuvants.

Morera Y, Bequet-Romero M, Ayala M, Lamdán H, Agger EM, Andersen P, Gavilondo JV.

Angiogenesis. 2008;11(4):381-93. doi: 10.1007/s10456-008-9121-5. Epub 2008 Nov 26.


Altered expression of 15-hydroxyprostaglandin dehydrogenase in tumor-infiltrated CD11b myeloid cells: a mechanism for immune evasion in cancer.

Eruslanov E, Kaliberov S, Daurkin I, Kaliberova L, Buchsbaum D, Vieweg J, Kusmartsev S.

J Immunol. 2009 Jun 15;182(12):7548-57. doi: 10.4049/jimmunol.0802358.

Supplemental Content

Support Center